SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : bluebird bio Inc. -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (72)5/23/2014 10:29:57 AM
From: idos  Read Replies (1) | Respond to of 163
 
Just note that the clinical trial you linked to is the USA one (HGB-204) and the Cavazzana abs is from the French (HGB-205) study.

investor.bluebirdbio.com

There are some preclinical data on the improved vector such as here:

abstracts2view.com

Nothing worrying.
On VCN: it is believed that between 0.3 - 3 at release should be ok (not too high to minimize the risks of insertional oncogenesis) and it may decrease in time.